National Comprehensive Cancer Network Oncology Research Program 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.NCCN Foundation Awards Grants to Five Young Investigators
The NCCN Foundation has awarded its sixth series of Young Investigator Awards to five oncology researchers from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.
FORT WASHINGTON, PA — The NCCN Foundation® has awarded grants to five young investigators from NCCN Member Institutions. These awardees, who are dedicated to advancing and discovering n... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - April 2, 2016 Category: Cancer & Oncology Source Type: news
Four Researchers Awarded Grants to Investigate Effectiveness of Nintedanib* in Lung, Colorectal, and Gastrointestinal Cancers
The NCCN ORP has awarded four research grants to investigate the effectiveness of nintedanib in non-small cell lung, colorectal, and gastrointestinal cancers.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib* (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal can... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 24, 2014 Category: Cancer & Oncology Source Type: news
NCCN Foundation
The NCCN Foundation® has awarded the fourth series of Young Investigator Awards to five young investigators from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.
FORT WASHINGTON, PA – The NCCN Foundation®, which, through private philanthropy, empowers people through knowledge and advances the mission of the National Comprehensive Cancer Netwo... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - May 29, 2014 Category: Cancer & Oncology Source Type: news
NCCN Receives $2 Million in Research Funding from Boehringer Ingelheim to Study Volasertib* in Hematologic Malignancies
The NCCN Oncology Research Program (ORP) received a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to facilitate studies of volasertib in hematologic malignancies.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the safety and clinical effectiveness... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - May 22, 2014 Category: Cancer & Oncology Source Type: news
Pharmacia Gives $3.15 Million Grant to NCCN to Advance Innovative Cancer Research Collaboration
-- NCCN to study clinical applications of therapies in treatment of breast, gynecological, and other forms of cancer --
[PEAPACK, NJ] – Pharmacia Corporation today announced it has provided a $3.15 million grant to the National Comprehensive Cancer Network (NCCN) for the development and review of clinical oncology research protocols and trials in breast, gynecological and other forms of cancer. The grant will provide funding for clinical research to identify treatment advances that improve p... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 15, 2013 Category: Cancer & Oncology Source Type: news
NCCN Qualifies Lehigh Valley Health Network for Affiliate Research Project
The NCCN Oncology Research Program has qualified Lehigh Valley Health Network, Lehigh Valley, PA, as the latest addition to its Affiliate Research Project. Lehigh Valley Health Network is a community-based affiliate of Moffitt Cancer Center—one of the 23 NCCN Member Institutions.
FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Affiliate Research Project (ARP), developed by the NCCN Oncology Research Program (ORP), has qualified Le... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 11, 2013 Category: Cancer & Oncology Source Type: news
Researchers Receive Grants from NCCN Oncology Research Program Funded through AVEO/Astellas Collaboration
The NCCN Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib as a result of funding through the AVEO/Astellas collaboration.
FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These gr... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - October 15, 2012 Category: Cancer & Oncology Source Type: news
Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded research grants to investigators following a review of proposals submitted in response to the NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4-million research grant from GlaxoSmithKline to scientifically evaluate and define clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212) in treatment of advanced mela... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 6, 2012 Category: Cancer & Oncology Source Type: news
NCCN Qualifies First Community Sites for Affiliate Research Project
The NCCN Oncology Research Program (ORP) has qualified seven sites from Fox Chase Cancer Center, Seattle Cancer Care Alliance, and University of Alabama at Birmingham as part of its Affiliate Research Project (ARP). The ARP is dedicated to improving patient outcomes and advancing clinical research through collaboration with NCCN, NCCN Member Institutions, and community-based affiliate networks.
FORT WASHINGTON, PA – The NCCN Affiliate Research Project (ARP), developed by the NCCN ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - July 10, 2012 Category: Cancer & Oncology Source Type: news
NCCN Collaborates with AVEO and Astellas on Innovative Cancer Research
NCCN recently received a research grant from AVEO Pharmaceuticals and Astellas Pharma, Inc. to evaluate the role of tivozanib in the treatment of solid tumors. Tivozanib is a potent, selective, long half-life inhibitor of all three VEGF receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.
FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that it has e... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - February 16, 2012 Category: Cancer & Oncology Source Type: news
NCCN Receives $2 Million in Oncology Research Funding from Boehringer Ingelheim to Investigate Afatinib in Solid Tumors
NCCN recently received a $2 million research grant from Boehringer Ingelheim Pharmaceuticals, Inc. to gain further insight into the use of the investigational compound Afatinib (BIBW 2992) in solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pha... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 10, 2011 Category: Cancer & Oncology Source Type: news
NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline
NCCN recently received $4 million in the form of two research grants from GlaxoSmithKline to gain further insights into GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor, both promising therapies in the treatment of advanced melanoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarde... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - October 11, 2011 Category: Cancer & Oncology Source Type: news
Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline
The NCCN Oncology Research Program received $4 million in research funding from GlaxoSmithKline to support research at NCCN Member Institutions in order to evaluate the effectiveness of ofatumumab (Arzerra®, GlaxoSmithKline) in hematologic malignancies and pazopanib (Votrient™, GlaxoSmithKline) in the treatment of solid tumors.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - August 31, 2011 Category: Cancer & Oncology Source Type: news
Researchers Receive Grants from NCCN Oncology Research Program Funded Through Pfizer
The NCCN Oncology Research Program received $2.1 million in research funding from Pfizer, Inc. to support research at NCCN Member Institutions in order to gain further insight into the use of axitinib in various tumor types.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network®`s (NCCN®`s) Oncology Research Program (ORP) recently awarded research grants to investigators following a review of proposals submitted in response to the NCCN Axitinib Request f... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - July 5, 2011 Category: Cancer & Oncology Source Type: news
NCCN Advances Oncology Imaging Research through the NCCN Specialized Imaging Research Consortium
NCCN has established the NCCN Specialized Imaging Research Consortium, a new initiative of the NCCN Oncology Research Program, to advance the treatment of patients with cancer through the clinical application of specialized imaging technologies.
FORT WASHINGTON, PA — Imaging plays an important role in clinical cancer care, and the increasing availability and use of advanced imaging methods have created a need for expertise in such techniques in order to guide their appropria... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - May 27, 2011 Category: Cancer & Oncology Source Type: news
